AstraZeneca buoyed as Imfinzi cuts lung cancer deaths by a third

The encouraging overall survival data boosts prospects for a medicine that was approved this week in Europe and has already had a promising U.S. commercial launch, based on its ability to slow disease progression. As the leading cause of cancer deaths, lung cancer represents the biggest opportunity for companies seeking to exploit the power of modern cancer immunotherapies. Deutsche Bank analysts said the "impressive" results would cement Imfinzi as the standard of care for lung cancer patients whose disease has not yet spread widely.

from Yahoo News - Latest News & Headlines https://ift.tt/2xWD1Nw